ArticlePoultry science2025
Chicken IL-17 as a potent adjuvant enhances IBDV VP2 DNA vaccine immunogenicity and protective efficacy.
Article in Poultry science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune protection in chickens via lipid nanoparticle-encapsulated VP2 DNA vaccine against very virulent infectious bursal disease virus.Poultry science · 2026Article
- Development of a recombinant chimeric Newcastle disease virus-vectored vaccine conferring single-dose, triple protection against genotype VII NDV, IBDV, and H9N2 AIV.Poultry science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bursal disease virus (IBDV) is an important immunosuppressive virus in chickens, which caused an acute and highly contagious infectious disease and resulted in considerable economic losses in the world poultry industry. Although IBDV VP2 DNA vaccine has been extensively proved only partial protection, the efficacy of DNA vaccines against IBDV can be augmented by choosing potential molecular adjuvants. To investigate whether chicken IL-17 (chIL-17) is qualified for the molecular adjuvant, we constructed chIL-17 gene vector, co-immunized chickens with chIL-17 gene vector and IBDV VP2 DNA vector, and analyzed the effect of IL-17 gene on the immunogenicity of VP2 DNA vaccine. Results showed that co-administrated chIL-17 gene and VP2 DNA vaccine significantly increased IBDV-specific serum antibody titer, and promoted lymphocyte proliferation and interference-γ (IFN-γ) production. Mechanically, chIL-17 reduced virus titer in bursa of fabricius tissue and mortality of IBDV-infected chicken. More importantly, chIL-17 gene significantly enhanced the protection induced by the VP2 gene against virulent IBDV infection.These data show that chIL-17 is a promising immunoadjuvant to facilitate humoral as well as cellular immunity in a vaccine setting against IBDV, and suggest that it should be evaluated as a new DNA vaccine adjuvant in strategies for other poultry diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.